The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chubykina S.V.

Pirogov Russian National Research Medical University

Tatarinova M.U.

Pirogov Russian National Research Medical University

Avakyan G.G.

Pirogov Russian National Research Medical University

Neuropathic pain caused by the toxic effect of chemotherapy in patients with malignant neoplasms

Authors:

Chubykina S.V., Tatarinova M.U., Avakyan G.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5): 7‑12

DOI: 10.17116/jnevro20231230517

Views: 2688

Downloaded: 69

Download PDF (RU)
Contact the author
Table of contents

NEUROPATHIC PAIN CAUSED BY THE TOXIC EFFECT OF CHEMOTHERAPY IN PATIENTS WITH MALIGNANT NEOPLASMS
NEUROPATHIC PAIN CAUSED BY THE TOXIC EFFECT OF CHEMOTHERAPY IN PATIENTS WITH MALIGNANT NEOPLASMS

To cite this article:

Chubykina SV, Tatarinova MU, Avakyan GG. Neuropathic pain caused by the toxic effect of chemotherapy in patients with malignant neoplasms. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5):7‑12. (In Russ.)
https://doi.org/10.17116/jnevro20231230517

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Features of course of pain syndrome in patients with schwannomatosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):48-52
The inte­nsity of neuropathic pain and the seve­rity of inso­mnia in diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):87-92
Modern and promising therapies for postherpetic neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):27-34
Como­rbid diso­rders and risk factors for neiropathic pain in distal diabetic poly­neuropathy. Russian Journal of Pain. 2024;(2):41-48
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2024;(10):7-20
Unre­solved problem: Chemotherapy-Induced Peri­pheral Neuropathy. P.A. Herzen Journal of Onco­logy. 2024;(5):76-81
Puri­nergic mechanisms of pain relief: fashionable topic or real oppo­rtunity to improve the quality of analgesic therapy?. Russian Journal of Pain. 2024;(4):86-95
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Psychoemotional health of patients with neuropathic pelvic pain under combined magnetic therapy. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(1):12-18
An inte­grated approach to reha­bilitation of patients with chemotherapy-induced poly­neuropathy. Current state of the problem. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(1):34-45

This article discusses chemotherapy-induced peripheral neuropathic pain (CIPNP) and its associated neuropathic pain syndrome that occurs in patients with malignant neoplasms (MN) during cytostatic therapy. The overall prevalence of CIPNP in patients with malignant neoplasms associated with chemotherapy with neurotoxic drugs is estimated, according to various sources, to be about 70%. The pathophysiological mechanisms of CIPNP have not been fully studied, but it is known that they are based on: impaired axonal transport, oxidative stress, induction of apoptosis, DNA damage, dysfunction of voltage-gated ion channels, and central mechanisms. It is important to recognize CIPNP in the clinical symptoms of patients with cancer treated with cytostatics, since these disorders can lead to serious restrictions in the motor, sensory and autonomic functions of the upper and lower extremities, as well as reduce the quality of life and daily functioning of such patients, forcing them to adjust the dose of chemotherapy drugs, transfer the next cycles and even interrupt the treatment of cancer carried out according to vital needs. In addition to the clinical examination, scales and questionnaires have been developed to identify symptoms of CIPNP, but it is most important for neurological and oncological specialists to know and be able to recognize such symptoms in patients. The mandatory research methods for identifying the symptoms of polyneuropathy include electroneuromyography (ENMG), which allows you to assess muscle activity, functional characteristics and the state of the function of peripheral nerves. The methods used to reduce symptoms are screening patients for the development of CIPNP and identifying patients at high risk of CIPNP and, if necessary, reducing the dose or changing cytostatics. Methods for correcting this disorder using different classes of drugs require more detailed study and further research.

Keywords:

chemoinduced polyneuropathy
neuropathic pain
chemotherapy
cytostatic therapy
postchemoinduced polyneuropathy
neurotoxicity

Authors:

Chubykina S.V.

Pirogov Russian National Research Medical University

Tatarinova M.U.

Pirogov Russian National Research Medical University

Avakyan G.G.

Pirogov Russian National Research Medical University

Received:

24.10.2022

Accepted:

30.01.2023

List of references:

  1. Kaprin AD. Malignant neoplasms In Russia in 2019 (morbidity and mortality). Kaprin A.D., Starinskiy V.V., Shahzadova A.O. M.: Moscow national Research oncology Institute named after P.A. Herzen — branch FGBU «NMITS radiology» of the Ministry of Health of Russia; 2020. (In Russ.). https://glavonco.ru/cancer_register/%D0%9F%D0%BE%D0%BC%D0%BE%D1%89%D1%8C%202019.pdf
  2. Leung B, Shokoohi A, Bates A, Ho C. Patient-reported psychosocial needs and psychological distress predict survival in geriatric oncology patients. Journal of Geriatric Oncology. 2020;12(4):612-617.  https://doi.org/10.1016/j.jgo.2020.10.001
  3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer Journal for Clinicians. 2021;71(3):209-249.  https://doi.org/10.3322/caac.21660
  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer Journal for Clinicians. 2020;70:7-30.  https://doi.org/10.3322/caac.21590
  5. Zolotovskayaia IA, Davydkin IL, Lokshtanova TM, Orlov AE. Clinical signs of chemotherapy-induced neuropathy in cancer patients and pharmacotherapy correction options. The Russian Archives of Internal Medicine. 2018;8(2):137-144. (In Russ.). https://doi.org/10.20514/2226-6704-2018-8-2-137-144
  6. Abbasov FA, Anikina MA, Zimnyakova OS, et al. Chemotherapy- associated polyneuropathy: problems and objects at the current stage of neurological assistance to oncological patients. Farmateka. 2017;17:78-82. (In Russ.). https://pharmateca.ru/en/archive/article/35542
  7. Mesheryakova AV, Zorkin EK. Deficiency of the peripheral nervous system in the structure of post-chemotherapeutic complications. Literature review. International Journal of Humanities and Natural Sciences. 2017;9(1):35-40. (In Russ.). https://intjournal.ru/wp-content/uploads/2017/10/Meshheryakova.pdf
  8. Mal T, Armes J, Ream E. The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. European Journal of Cancer Care. 2017;26(5):e12443. https://doi.org/10.1111/ecc.12443
  9. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Support Care Cancer. 2004;12(9):619-625.  https://doi.org/10.1007/s00520-004-0657-7
  10. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nature Reviews Neurology. 2010;6(12):657-666.  https://doi.org/10.1038/nrneurol.2010.160
  11. Beijers A, Mols F, Dercksen D, et al. Chemotherapy-induced peripheral neuropathy and impacton quality of life after treatment with chemotherapy. The Journal of Supportive Oncology. 2014;12:401-406.  https://doi.org/10.12788/jcso.0086
  12. Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nursing Research. 2007;56:323-331.  https://doi.org/10.1097/01.NNR.0000289503.22414.79
  13. Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. Journal of Palliative Medicine. 2010;13:1389-1391. https://doi.org/10.1089/jpm.2010.0124
  14. Mols F, Beijers T, Vreugdenhil G, Lonneke van de Poll-Franse. Chemotherapy- induced peripheral neuropathy and its association with quality of life: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2014;22:2261-2269. https://doi.org/10.1007/s00520-014-2255-7
  15. Semenova AI. Cardio- and neurotoxicity of anticancer drugs (pathogenesis, clinic, prevention, treatment). Practical Oncology. 2009;10(3):168-176. (In Russ.). https://practical-oncology.ru/journal/kardio-i-neyrotoksichnost-protivoopukholevykh-preparatov-patogenez-klinika-profilaktika-lechenie
  16. Beznosov EV, Lebedev IA, Zotov PB, et al. Polyneuropathies in malignant neoplasms: Diagnosis, treatment, and rehabilitation (review). Palliativnaya meditsina i reabilitatsiya. 2019;2:47-51. (In Russ). https://www.palliamed.ru/publications/pub146/number162/
  17. Kondratiev VB, Karasev NA. Treatment and prevention of complications of chemotherapy with platinum and taxanes. Prakticheskaya onkologiya. 2000;3:38-42. (In Russ.). https://rosoncoweb.ru/library/journals/practical_oncology/arh003/08.pdf
  18. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. British Journal of Anaesthesia. 2017;119:737-749.  https://doi.org/10.1093/bja/aex229
  19. Kinga S. Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy. Pharmacol Rep. 2020;72(3):486-507.  https://doi.org/10.1007/s43440-020-00109-y
  20. Hausheer F, Schilsky R, Bain S, et al. Diagnosis, Management and Evaluation of Chemotherapy-Induced Peripheral Neuropathy. Seminars in Oncology. 2006;33(1):15-49.  https://doi.org/10.1053/j.seminoncol.2005.12.010
  21. Schneider B, Li L, Radovich M, et al. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clinical Cancer Research. 2015;21(22):5082-5091. https://doi.org/10.1158/1078-0432.ccr-15-0586
  22. Burgess J, Ferdousi M, Gosal D, et al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncology and Therapy. 2021;9:385-450.  https://doi.org/10.1007/s40487-021-00168-y
  23. Linkov MV, Usova NN. Chemo-induced polyneuropathies as a complication of multiple myeloma therapy. Medicinskie Novosti. 2021;1(316):37-39. (In Russ.). https://elibrary.ru/download/elibrary_44692314_87920205.pdf
  24. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. department of health and human services. National Institutes of Health. National Cancer Institute. 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
  25. Kovtun OP, Bazarny VV, Koryakina OV, Abdullaev AN. Neurotoxic Complications of Chemotherapy in Children. Literature Review. Pediatric pharmacology. 2020;17(1):12-17. (In Russ.). https://doi.org/10.15690/pf.v17i1.2077
  26. Danilov AB. Nejropaticheskaya bol`. Klinicheskaya gerontologiya. 2007;2:27-36. (In Russ.).
  27. Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Frontiers in Molecular Neuroscience. 2017;10:174.  https://doi.org/10.3389/fnmol.2017.00174
  28. Sahenk Z, Barohn R, New P, et al. Taxol neuropathy. Electrodiagnostic and Sural Nerve Biopsy Findings. Archives of Neurology. 1994;51(7):9.  https://doi.org/10.1001/archneur.1994.00540190110024
  29. Park SB, Krishnan AV, Lin CS, et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Current Medicinal Chemistry. 2008;15(29):3081-3094. https://doi.org/10.2174/092986708786848569
  30. Staff NP, Podratz JL, Grassner L, et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology. 2013;39(1):124-131.  https://doi.org/10.1016/j.neuro.2013.09.001
  31. Vatutin NT, Sklyannaya EV, El-Khatib MA, et al. Peripheral neurophathies induced by various chemotherapeutic agents: current state of the problem. Hematology and Transfusiology. Russian journal = Gematologiya i transfusiologiya. 2016;61(2):105-109. (In Russ.).
  32. Zajączkowska R, Kocot-Kępska M, Leppert W, et al. Mechanisms of chemotherapy-induced peripheral neuropathy. International Journal of Molecular Sciences. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451
  33. Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Critical Reviews in Oncology/Hematology. 2020;145:102831. https://doi.org/10.1016/j.critrevonc.2019.102831
  34. Tkachenko EV, Andreev VV, Yatsenko AV, et al. Neurotoxicity as a side effect of taxanes in cancer patients. Russian Journal of Pain. 2020;18(3):48-53. (In Russ.). https://doi.org/10.17116/pain20201803148
  35. Kholodova NB, Ponkratova IuA, Sinkin MV. Clinical and electromyography characteristics of chemotherapy-induced polyneuropathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(9):59-66. (In Russ.). https://doi.org/10.17116/jnevro20171179159-66
  36. Kandula T, Farrar MA, Kiernan MC, et al. Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology. 2017;128:1166-1175. https://doi.org/10.1016/j.clinph.2017.04.009
  37. Argyriou AA, Koltzenburg M, Polychronopoulos P, et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Critical Reviews in Oncology/Hematology. 2008;66(3):218-228.  https://doi.org/10.1016/j.critrevonc.2008.01.008
  38. Streckmann F, Balke M, Lehmann HC, et al. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies — STOP. BMC Cancer. 2018;18:62.  https://doi.org/10.1186/s12885-017-3866-4
  39. Streckmann F, Lehmann HC, Balke M, et al. Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy — a randomized controlled pilot trial. Support Care Cancer. 2019;27:2471-2478. https://doi.org/10.1007/s00520-018-4531-4
  40. Taleb O, Bouzobra F, Tekin-Pala H, et al. Behavioral and electromyographic assessment of oxaliplatin-induced motor dysfunctions: evidence for a therapeutic effect of allopregnanolone. Behav Brain Res. 2017;320:440-449.  https://doi.org/10.1016/j.bbr.2016.10.040
  41. Cascella M, Di Napoli R, Carbone D, et al. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives. Recenti Prog Med. 2018;109(11):523-530.  https://doi.org/10.1701/3031.30289
  42. Khalil R. B. «Emotional Chemobrain»: A new concept for chemotherapy adverse drug effect? Encephale. 2021;47(6):613-615.  https://doi.org/10.1016/j.encep.2020.08.005
  43. Argyriou A, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology. Hematology. 2012;82(1):51-77.  https://doi.org/10.1016/j.critrevonc.2011.04.012
  44. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
  45. Soffietti R, Trevisan E, Ruda R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handbook of Clinical Neurology. 2014;121:1199-1218. https://doi.org/10.1016/B978-0-7020-4088-7.00080-8
  46. Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. Journal of Neurology. 2012;259:1936-1943. https://doi.org/10.1007/s00415-012-6442-5
  47. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer. 2005b;13:647-651.  https://doi.org/10.1007/s00520-005-0776-9
  48. Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology. 2009a;27:1243-1249. https://doi.org/10.1200/JCO.2008.19.3425
  49. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009c;132:2712-2723. https://doi.org/10.1093/brain/awp219
  50. Kokotis P, Schmelz M, Kostouros E, et al. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study. Clinical colorectal cancer. 2016;15(3):133-140.  https://doi.org/10.1016/j.clcc.2016.02.009
  51. New PZ, Jackson CE, Rinaldi D, et al. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology. 1996;46:108-111.  https://doi.org/10.1212/wnl.46.1.108
  52. Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: Clinical and neurophysiological study of 23 patients. Ital J Neurol Sci. 1997;18(2):73-79.  https://doi.org/10.1007/BF01999566
  53. Chen X, Stubblefield MD, Custodio CM, et al. Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer. Journal of Clinical Neurophysiology. 2013;30:199-203.  https://doi.org/10.1097/WNP.0b013e3182767d3b
  54. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96:69-86.  https://doi.org/10.1093/brain/96.1.69
  55. Briani C, Zara G, Rondinone R, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004;62:2288-2290. https://doi.org/10.1212/01.WNL.0000130499.91775.2C
  56. Hershman DL, Lacchetti C, Dworkin RH, et al. American Society of Clinical Oncology Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2014;32(18):1941-1967. https://doi.org/10.1200/JCO.2013.54.0914
  57. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. Journal of Clinical Oncology. 2020;1:38(28):3325-3348. https://doi.org/10.1200/JCO.20.01399
  58. Jordan B, Jahn F, Sauer S, Jordan K. Prevention and Management of Chemotherapy-Induced Polyneuropathy. Breast Care. 2019;14(2):79-84.  https://doi.org/10.1159/000499599

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.